Clinical Trial Update: MagDI Diversion Feasibility Study [NA]

View source ↗

Summary

The MagDI Diversion Feasibility Study has been completed for Type 2 Diabetes and Obesity, sponsored by GT Metabolic Solutions, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• MagDI Diversion

Snippet

Sponsor: GT Metabolic Solutions, Inc. | Conditions: Type 2 Diabetes, Obesity | NA | Status: COMPLETED